Starpharma Holdings Limited – OTC:SPHRY
Starpharma Holdings Limited stock price today
$0.845
+0.22
+35.6%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Starpharma Holdings Limited stock price monthly change
+3.83%
month
Starpharma Holdings Limited stock price quarterly change
+3.83%
quarter
Starpharma Holdings Limited stock price yearly change
-50.16%
year
Starpharma Holdings Limited key metrics
Market Cap | 164.76M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.05 |
Revenue | 7.57M |
EBITDA | -29.23M |
Income | -22.59M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -385.93% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeStarpharma Holdings Limited stock price history
Starpharma Holdings Limited stock forecast
Starpharma Holdings Limited financial statements
| Mar 2022 | 1.55M | -3.85M | -247.11% |
|---|---|---|---|
| Jun 2022 | 2.86M | -7.70M | -269.12% |
| Mar 2023 | 1.30M | -3.68M | -283.01% |
| Jun 2023 | 1.85M | -7.36M | -397.25% |
| Sep 2022 | 57646000 | 16.62M | 28.84% |
|---|---|---|---|
| Dec 2022 | 57646000 | 16.62M | 28.84% |
| Mar 2023 | 52086000 | 17.27M | 33.16% |
| Jun 2023 | 52086000 | 17.27M | 33.16% |
| Mar 2022 | -959.5K | -321.5K | 599K |
|---|---|---|---|
| Jun 2022 | -1.91M | -643K | 1.19M |
| Mar 2023 | -4.22M | -73.5K | -177.5K |
| Jun 2023 | -8.45M | -147K | -355K |
Starpharma Holdings Limited alternative data
| Aug 2023 | 50 |
|---|---|
| Sep 2023 | 45 |
| Oct 2023 | 45 |
| Nov 2023 | 45 |
| Dec 2023 | 45 |
| Jan 2024 | 45 |
| Feb 2024 | 45 |
| Mar 2024 | 45 |
| Apr 2024 | 45 |
| May 2024 | 45 |
| Jun 2024 | 45 |
| Jul 2024 | 45 |
Starpharma Holdings Limited other data
-
What's the price of Starpharma Holdings Limited stock today?
One share of Starpharma Holdings Limited stock can currently be purchased for approximately $0.85.
-
When is Starpharma Holdings Limited's next earnings date?
Unfortunately, Starpharma Holdings Limited's (SPHRY) next earnings date is currently unknown.
-
Does Starpharma Holdings Limited pay dividends?
No, Starpharma Holdings Limited does not pay dividends.
-
How much money does Starpharma Holdings Limited make?
Starpharma Holdings Limited has a market capitalization of 164.76M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 231.95% to 9.76M US dollars.
-
What is Starpharma Holdings Limited's stock symbol?
Starpharma Holdings Limited is traded on the OTC under the ticker symbol "SPHRY".
-
What is Starpharma Holdings Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Starpharma Holdings Limited?
Shares of Starpharma Holdings Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Starpharma Holdings Limited have?
As Jul 2024, Starpharma Holdings Limited employs 45 workers.
-
When Starpharma Holdings Limited went public?
Starpharma Holdings Limited is publicly traded company for more then 20 years since IPO on 29 Dec 2004.
-
What is Starpharma Holdings Limited's official website?
The official website for Starpharma Holdings Limited is starpharma.com.
-
Where are Starpharma Holdings Limited's headquarters?
Starpharma Holdings Limited is headquartered at 4-6 Southampton Crescent, Abbotsford, VIC.
-
How can i contact Starpharma Holdings Limited?
Starpharma Holdings Limited's mailing address is 4-6 Southampton Crescent, Abbotsford, VIC and company can be reached via phone at +61 3 8532 2700.
Starpharma Holdings Limited company profile:
Starpharma Holdings Limited
starpharma.comExchange:
OTC
Full time employees:
50
Industry:
Biotechnology
Sector:
Healthcare
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
4-6 Southampton Crescent
Abbotsford, VIC 3067
Abbotsford, VIC 3067
:
ISIN: US8555631022
:
